Effects of neurofeedback on major depressive disorder: a systematic review.
Einstein (Sao Paulo)
; 21: eRW0253, 2023.
Article
en En
| MEDLINE
| ID: mdl-37493834
ABSTRACT
BACKGROUND:
Major depressive disorder is a difficult-to-treat psychological disorder. Approximately 30% of patients with major depressive disorder do not respond to conventional therapies; thus, the efficacy of alternative therapies for treating major depressive disorder, such as neurofeedback, a non-invasive neuromodulation method used in the treatment of psychiatric diseases, must be investigated.OBJECTIVE:
We aimed to evaluate the efficacy of neurofeedback in minimizing and treating major depressive disorder and its application as a substitute to or an adjuvant with conventional therapies.METHODS:
We searched for experimental studies published between 1962-2021 in Scopus, PubMed, Web of Science, and Embase databases and identified 1,487 studies, among which 13 met the inclusion exclusion criteria.RESULTS:
We noted that not all patients responded to neurofeedback. Based on depression scales, major depressive disorder significantly improved in response to neurofeedback only in a few individuals. Additionally, the number of training sessions did not influence the results.CONCLUSION:
Neurofeedback can reduce depression symptoms in patients; however, not all patients respond to the treatment. Therefore, further studies must be conducted to validate the effectiveness of neurofeedback in treating major depressive disorder.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Trastorno Depresivo Mayor
/
Neurorretroalimentación
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Einstein (Sao Paulo)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Brasil